Hepatitis C virus entry: possible targets for therapy.
Timpe
J M
JM
Institute for Biomedical Research, The Medical School, Vincent Drive, Birmingham B15 2TT, UK.
McKeating
J A
JA
D000818:Animals; D015703:Antigens, CD / Q000502:physiology; D000998:Antiviral Agents / Q000627:therapeutic use; D016679:Genome, Viral; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000628:therapy* / Q000635:transmission / Q000821:virology; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D008074:Lipoproteins / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism*; D010750:Phosphoproteins / Q000378:metabolism*; D051122:Scavenger Receptors, Class B / Q000037:antagonists & inhibitors / Q000378:metabolism; D060225:Tetraspanin 28; D014771:Virion / Q000502:physiology; D053585:Virus Attachment; D016662:Virus Integration / Q000502:physiology*; D014779:Virus Replication / Q000502:physiology; D062826:Zonula Occludens-1 Protein
D015703:Antigens, CD; D000998:Antiviral Agents; C554798:CD81 protein, human; D008074:Lipoproteins; D008565:Membrane Proteins; D010750:Phosphoproteins; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; C569042:TJP1 protein, human; D060225:Tetraspanin 28; D062826:Zonula Occludens-1 Protein